CAROLINA DE QUEIROZ SACRAMENTO

Bacharel em Biomedicina pela Universidade Federal do Rio de Janeiro (2011), Mestre (2013) e Doutora (2017) em Biologia Celular e Molecular com ênfase em Farmacologia e Imunologia pelo Instituto Oswaldo Cruz (IOC)/FIOCRUZ, sendo agraciada com o Prêmio Anual IOC de Teses Alexandre Peixoto (2018). Atualmente, é pós doutoranda do núcleo de desenvolvimento pré-clínico de antivirais do Centro de Desenvolvimento Tecnológico em Saúde (CDTS)/FIOCRUZ, pelo Programa de Pós-doutorado Nota 10 (FAPERJ) no Laboratório de Imunofarmacologia do IOC/FIOCRUZ. Trabalha também em parcerias internacionais com a Universidade de Columbia (Nova Iorque/EUA) através do Metropolitan AntiViral Drug Accelerator (MAVDA) e com o DNDi, através da Aliança Dengue. Atua na área de desenvolvimento pré-clínico de antivirais contra vírus emergentes e de importância clínica, como dengue, zika, Chikungunya, febre amarela, HIV, influenza e SARS-CoV-2. Orientou alunos de iniciação científica (6), trabalhos de conclusão de curso (5) e dissertação de mestrado (1). Atualmente, orienta alunos de mestrado (1) e doutorado (1). Durante seu doutorado e pós doutoramento, publicou diversos trabalhos de alto impacto em revistas do grupo Nature (Nature Communications, Communications Biology e Scientific Reports), grupo PLoS (PLoS Pathogens, PLoS Neglected Infectious Diseases e PLoS One), Microbiome e Emerging Infectious Diseases. Recebeu menção honrosa no II Simpósio Hermann Schatzmayr de Virologia do IOC/FIOCRUZ (2013) e prêmio de melhor trabalho apresentado no 32nd International Conference on Antiviral Research da International Society for Antiviral Research (ISAR) na categoria de Pós doutorado (2019). Experiência nas áreas de Virologia, Farmacologia, Biologia Celular e Molecular, e Imunologia.

Carolina concluded her bachelor in Biomedicine at the Federal University of Rio de Janeiro (2011), Master (2013) and PhD (2017) in Cellular and Molecular Biology with an emphasis on Pharmacology and Immunology at the Oswaldo Cruz Institute (IOC)/FIOCRUZ, being awarded the Annual Thesis Prize Alexandre Peixoto from IOC/FIORCRUZ (2018). Currently, she is a post-doctoral research at the core of preclinical development of antivirals at the Center for Technological Development in Health (CDTS)/FIOCRUZ, with scholarship provided by FAPERJ (Nota 10 Postdoctoral Program), developing her research at the Laboratory of Immunopharmacology of IOC/FIOCRUZ. She also works in partnerships with Columbia University (New York/USA) through the Metropolitan AntiViral Drug Accelerator (MAVDA) and with DNDi, through the Dengue Alliance. She is specialized in the area of preclinical development of antivirals against emerging and clinically important viruses, such as dengue, zika, chikungunya, yellow fever, HIV, influenza and SARS-CoV-2. She supervised scientific initiation students (6), bachelor/undergraduate conclusion projects (5) and master's dissertations (1). Currently, she advises master's (1) and doctoral (1) students. During her PhD and postdoctoral projects, she published several relevant papers in journals from Nature`s group (Nature Communications, Communications Biology and Scientific Reports), PLoS` group (PLoS Pathogens, PLoS Neglected Infectious Diseases and PLoS One), Microbiome and Emerging Infectious Diseases. Throughout her carrier, she received an honorable mention at the II Symposium Hermann Schatzmayr of Virology of IOC/FIOCRUZ (2013) and was awarded for the best work at the 32nd International Conference on Antiviral Research of the International Society for Antiviral Research (ISAR) in the Postdoctoral category (2019). She has experience in the areas of Virology, Pharmacology, Cellular and Molecular Biology, and Immunology.